(Q36118370)

12 August 2017

1 reference

title

Docetaxel in the management of ovarian cancer (English)

1 reference

12 August 2017

1 reference

1 reference

Sarah P Blagden

1

1 reference

12 August 2017

Stan B Kaye

series ordinal

2

1 reference

12 August 2017

language of work or name

1 reference

1 April 2005

1 reference

Expert Review of Anticancer Therapy

12 August 2017

published in

1 reference

12 August 2017

volume

5

1 reference

12 August 2017

issue

2

1 reference

12 August 2017

page(s)

203-214

1 reference

The taxanes: toxicity and quality of life considerations in advanced ovarian cancer

12 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.203

Docetaxel and cisplatin in combination as first-line chemotherapy for advanced epithelial ovarian cancer. Scottish Gynaecological Cancer Trials Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.203

Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.203

Peripheral neuropathy secondary to docetaxel (Taxotere)

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.203

Promotion of microtubule assembly in vitro by taxol

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.203

Crystal and molecular structure of paclitaxel (taxol).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.203

Microtubules as a target for anticancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.203

Mechanisms of action of and resistance to antitubulin agents: microtubule dynamics, drug transport, and cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.203

S-phase specificity of cell killing by docetaxel (Taxotere) in synchronised HeLa cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.203

Chemistry and chemical biology of taxane anticancer agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.203

Preclinical pharmacology of the taxanes: implications of the differences.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.203

Comparison of antiangiogenic activities using paclitaxel (taxol) and docetaxel (taxotere).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.203

Taxane-mediated gene induction is independent of microtubule stabilization: induction of transcription regulators and enzymes that modulate inflammation and apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.203

Taxane-platinum combinations in advanced non-small cell lung cancer: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.203

The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.203

Cremophor EL causes (pseudo-) non-linear pharmacokinetics of paclitaxel in patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.203

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.203

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.203

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.203

Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.203

Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.203

First-line treatment for advanced ovarian cancer: paclitaxel, platinum and the evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.203

Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials. Advanced Ovarian Cancer Trialists' Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.203

Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.203

Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.203

Is optimal first-line chemotherapy deliverable in all newly diagnosed ovarian cancers? A population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.203

Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.203

Part II: chemotherapy for epithelial ovarian cancer-treatment of recurrent disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.203

Early clinical studies with docetaxel. Docetaxel Investigators Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.203

Docetaxel: an active new drug for treatment of advanced epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.203

Phase II trial of docetaxel in patients with platinum-refractory advanced ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.203

Phase II trials of docetaxel (Taxotere) in advanced ovarian cancer--an updated overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.203

The integration of docetaxel into first-line chemotherapy for ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.203

A multicenter phase II study of cisplatin and docetaxel (Taxotere) in the first-line treatment of advanced ovarian cancer: a GINECO study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.203

Docetaxel-carboplatin as first line chemotherapy for epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.203

Docetaxel versus paclitaxel for adjuvant treatment of ovarian cancer: case-control analysis of toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.203

A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.203

A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.203

Docetaxel for patients with paclitaxel-resistant Müllerian carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.203

Herceptin raises its sights beyond advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.203

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.203

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.203

Simultaneous blockade of platelet-derived growth factor-receptor and epidermal growth factor-receptor signaling and systemic administration of paclitaxel as therapy for human prostate cancer metastasis in bone of nude mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.203

Measuring treatment preferences and willingness to pay for docetaxel in advanced ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.203

Quality of life as a primary end point in oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.203

Docetaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.203

Clinical characteristics of severe peripheral neuropathy induced by docetaxel (Taxotere).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.203

Neurotoxic complications of chemotherapy in patients with cancer: clinical signs and optimal management

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.203

Improvement of paclitaxel-induced neuropathy by substitution of docetaxel for paclitaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.203

Mechanism of taxane neurotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.203

The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.203

Development of a European Organization for Research and Treatment of Cancer questionnaire module to assess the quality of life of ovarian cancer patients in clinical trials: a progress report.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.2.203

21 January 2018

Identifiers

DOI

10.1586/14737140.5.2.203

1 reference

12 August 2017

1 reference